HIK.L vs. SNN
HIK.L (Hikma Pharmaceuticals plc) and SNN (Smith & Nephew plc) are both stocks. Both are in the Healthcare sector — HIK.L in Drug Manufacturers - Specialty & Generic, SNN in Medical Devices. Over the past 10 years, HIK.L returned -2.28%/yr vs 1.98%/yr for SNN. At a 0.25 correlation, their price movements are largely independent.
Performance
HIK.L vs. SNN - Performance Comparison
Loading charts...
Different Trading Currencies
HIK.L is traded in GBp, while SNN is traded in USD. To make them comparable, the SNN values have been converted to GBp using the latest available exchange rates.
Returns By Period
In the year-to-date period, HIK.L achieves a -3.15% return, which is significantly higher than SNN's -4.34% return. Over the past 10 years, HIK.L has underperformed SNN with an annualized return of -2.28%, while SNN has yielded a comparatively higher 1.98% annualized return.
HIK.L
- 1D
- 3.11%
- 1M
- 3.47%
- YTD
- -3.15%
- 6M
- -5.58%
- 1Y
- -27.44%
- 3Y*
- -3.58%
- 5Y*
- -6.83%
- 10Y*
- -2.28%
SNN
- 1D
- -0.15%
- 1M
- 3.08%
- YTD
- -4.34%
- 6M
- -7.25%
- 1Y
- 5.21%
- 3Y*
- 0.64%
- 5Y*
- -2.66%
- 10Y*
- 1.98%
HIK.L vs. SNN - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
HIK.L Hikma Pharmaceuticals plc | -3.15% | -19.62% | 14.90% | 18.37% | -28.40% | -10.43% | 28.87% | 18.12% | 54.10% | -39.17% |
SNN Smith & Nephew plc | -4.34% | 27.07% | -5.72% | -0.78% | -10.71% | -15.42% | -13.03% | 25.87% | 15.35% | 8.32% |
Correlation
The correlation between HIK.L and SNN is 0.21, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.21 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.14 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.20 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.26 |
Correlation (All Time) Calculated using the full available price history since Jul 4, 2007 | 0.25 |
The correlation between HIK.L and SNN shifts across timeframes, from 0.14 (3 years) to 0.26 (10 years), reflecting how their relationship changes across market environments.
Fundamentals
HIK.L:
£3.26B
SNN:
$13.36B
HIK.L:
£3.41
SNN:
$2.37
HIK.L:
4.28
SNN:
12.92
HIK.L:
0.33
SNN:
0.45
HIK.L:
0.50
SNN:
1.12
HIK.L:
1.26
SNN:
2.53
HIK.L:
£6.48B
SNN:
$11.99B
HIK.L:
£2.80B
SNN:
$8.25B
HIK.L:
£1.46B
SNN:
$2.82B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
HIK.L vs. SNN — Risk / Return Rank
HIK.L
SNN
HIK.L vs. SNN - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Hikma Pharmaceuticals plc (HIK.L) and Smith & Nephew plc (SNN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| HIK.L | SNN | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.01 | ||
| Sortino ratioReturn per unit of downside risk | -1.42 | ||
| Omega ratioGain probability vs. loss probability | 0.85 | 1.07 | -0.22 |
| Calmar ratioReturn relative to maximum drawdown | -0.63 | 0.22 | -0.85 |
| Martin ratioReturn relative to average drawdown | -1.10 | 0.48 | -1.58 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| HIK.L | SNN | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.83 | 0.18 | -1.01 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.25 | -0.11 | -0.14 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | -0.07 | 0.08 | -0.15 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.32 | 0.21 | +0.11 |
Drawdowns
HIK.L vs. SNN - Drawdown Comparison
The maximum HIK.L drawdown since its inception was -67.40%, which is greater than SNN's maximum drawdown of -51.13%. Use the drawdown chart below to compare losses from any high point for HIK.L and SNN.
Loading charts...
Drawdown Indicators
| HIK.L | SNN | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -67.40% | -51.13% | -16.27% |
Max Drawdown (1Y)Largest decline over 1 year | -43.67% | -23.64% | -20.03% |
Max Drawdown (3Y)Largest decline over 3 years | -47.40% | -29.18% | -18.22% |
Max Drawdown (5Y)Largest decline over 5 years | -54.46% | -40.79% | -13.67% |
Max Drawdown (10Y)Largest decline over 10 years | -67.40% | -51.13% | -16.27% |
Current DrawdownCurrent decline from peak | -37.14% | -32.47% | -4.67% |
Average DrawdownAverage peak-to-trough decline | -19.55% | -16.99% | -2.56% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 25.02% | 10.89% | +14.13% |
Volatility
HIK.L vs. SNN - Volatility Comparison
The current volatility for Hikma Pharmaceuticals plc (HIK.L) is 6.63%, while Smith & Nephew plc (SNN) has a volatility of 7.17%. This indicates that HIK.L experiences smaller price fluctuations and is considered to be less risky than SNN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| HIK.L | SNN | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.63% | 7.17% | -0.54% |
Volatility (6M)Calculated over the trailing 6-month period | 26.21% | 17.60% | +8.61% |
Volatility (1Y)Calculated over the trailing 1-year period | 32.98% | 29.11% | +3.87% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 27.78% | 25.39% | +2.39% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 31.64% | 25.62% | +6.02% |
Dividends
HIK.L vs. SNN - Dividend Comparison
HIK.L's dividend yield for the trailing twelve months is around 4.25%, more than SNN's 2.55% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
HIK.L Hikma Pharmaceuticals plc | 4.25% | 4.13% | 3.08% | 2.76% | 2.71% | 1.70% | 1.44% | 1.71% | 1.48% | 2.19% | 1.21% | 0.89% |
SNN Smith & Nephew plc | 2.55% | 2.32% | 3.05% | 2.75% | 2.79% | 2.17% | 1.78% | 1.51% | 1.96% | 1.76% | 2.08% | 1.68% |
Financials
HIK.L vs. SNN - Financials Comparison
This section allows you to compare key financial metrics between Hikma Pharmaceuticals plc and Smith & Nephew plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
HIK.L vs. SNN - Profitability Comparison
HIK.L - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Hikma Pharmaceuticals plc reported a gross profit of 673.22M and revenue of 1.70B. Therefore, the gross margin over that period was 39.6%.
SNN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Smith & Nephew plc reported a gross profit of 2.09B and revenue of 3.19B. Therefore, the gross margin over that period was 65.6%.
HIK.L - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Hikma Pharmaceuticals plc reported an operating income of 305.46M and revenue of 1.70B, resulting in an operating margin of 18.0%.
SNN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Smith & Nephew plc reported an operating income of 570.45M and revenue of 3.19B, resulting in an operating margin of 17.9%.
HIK.L - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Hikma Pharmaceuticals plc reported a net income of 164.79M and revenue of 1.70B, resulting in a net margin of 9.7%.
SNN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Smith & Nephew plc reported a net income of 330.82M and revenue of 3.19B, resulting in a net margin of 10.4%.
Frequently Asked Questions
HIK.L and SNN have a correlation of 0.21, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for HIK.L and SNN
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer